Bio-Rad Laboratories, Inc. BIO.B
365.08
0.00
0.00%
as of 24 Sep
- Market cap
- $10.3B
- P/E
- 43.8×
Follow BIO.B
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 3.11% | 2.50% | 10.84% | (9.50%) |
+8 more TTM periods Free account |
|
| 2.17% | 1.75% | 7.62% | (6.66%) | ||
ROIC |
0.49% | 0.55% | 0.41% | 2.15% | |
Return on Tangible Assets |
8.63% | 6.61% | 25.94% | (23.63%) | |
Average Days of Receivables |
62.28 | 60.07 | 65.08 | 66.32 | |
Free Cash Flow per Share |
13.20 | 13.26 | 13.74 | 12.51 | |
Free Cash Flow |
353.10 | 357.40 | 374.70 | 336.90 | |
Capital Expenditures |
(139.50) | (153.00) | (157.50) | (154.60) | |
Piotroski F-Score |
4.00 | 6.00 | 5.00 | 4.00 | |
| Other line items | |||||
Cash ROIC |
4.93% | 5.31% | 5.22% | 5.25% | |
Accounts Receivable Turnover |
5.68 | 6.09 | 5.66 | 5.52 | |
Accounts Payable Turnover |
8.81 | 9.20 | 9.89 | 9.73 | |
Inventory Turnover |
1.58 | 1.60 | 1.66 | 1.54 | |
Average Days of Payables |
42.05 | 38.97 | 37.87 | 38.51 | |
Days of Inventory on Hand |
228.76 | 225.60 | 217.45 | 234.16 | |
Tax Rate |
(0.37) | (0.24) | (0.24) | (0.20) | |
Research and Development Expense of Revenue |
10.29% | 0.00% | 0.00% | 11.59% | |
Selling, General and Administrative Expense of Revenue |
32.91% | 32.74% | 32.68% | 32.35% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
2.21 | 3.02 | 0.70 | (0.73) | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
96.81 | 96.07 | 94.75 | 94.99 | |
Operating CF per Share |
18.42 | 18.93 | 19.52 | 18.26 | |
Capex per Share |
(5.22) | (5.68) | (5.78) | (5.74) | |
Capex to Sales |
0.05 | 0.06 | 0.06 | 0.06 | |
Net Profit Margin |
8.59% | 6.52% | 29.42% | (26.43%) |
Columns are period end dates